In individuals with type 1 diabetes, in whom virtually no functional beta-cell population remains and insulin is administered exogenously, reduced exogenous insulin dosing associated with dapagliflozin could have led to higher glucagon concentrations through reduced suppression of alpha-cell activity and a counter-regulatory response [14]. This evidence concerns the gene INS and type 1 diabetes mellitus.